March 26, 2021By Randall C WillisSpecial Report on Neuroscience: Demystifying psychedelicsResearchers add analysis to the mix to move beyond anecdotes
March 30, 2021By DDN StaffDeep brain stimulation for Parkinson's diseaseNew discoveries suggest it is on par with therapeutics and speeds the process of recovery and adoption of personalized treatment
March 29, 2021By DDN StaffBringing siRNA across the barrierBioasis announces publication evaluating CNS delivery of siRNA via the company’s xB³ platform
March 26, 2021By Jeffrey BouleyFocus Feature on Neuroscience: Preclinical progress on neurodegenerationMaking the rounds of brain-related therapeutic and diagnostic R&D, with a focus on neurodegenerative disease and dementia
Other Internal MedicineMarch 25, 2021By Kelsey KaustinenBrain biomarkers for depression and traumaCombining machine learning and EEG may have identified an imaging biomarker for better treating PTSD and MDD
DiscoveryMarch 25, 2021By Ilene SchneiderClues to complexityStudy determines genetic variants of PTSD
March 24, 2021By Mel J. YeatesBetterLife and UCSD partner on LSD derivativeBetterLife enters research agreement with UCSD for TD-0148A behavioral pharmacology studies
DiscoveryMarch 24, 2021By DDN StaffCholesterol may be key to new Alzheimer’s and diabetes therapiesUniversity of Arizona researcher looks beyond traditional causes to find novel therapies
March 17, 2021By DDN StaffCould DMT be beneficial in stroke recovery?Algernon Pharmaceuticals submits pre-IND meeting request for clinical research program in DMT for stroke
Business & Policy NewsMarch 15, 2021By DDN StaffIntelGenx and atai partner up on psychedelicsIntelGenx announces strategic partnership with atai Life Sciences; agreement also includes equity investment by atai
Preclinical ResearchMarch 10, 2021By DDN StaffData to build onYumanity's YTX-7739 prevents motor function deficits, leads to improved survival of dopaminergic neurons in Parkinson’s disease mouse model